公开(公告)号：US11129796B2

公开(公告)日：2021-09-28

申请号：US16483830

申请日：2018-02-06

Applicant: LEMONEX INC.

Inventor： Cheolhee Won

IPC: A61K9/16 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/203 ,  A61K38/17 ,  A61K31/713 ,  A61K31/711 ,  A61K39/395 ,  A61K38/46

Abstract: A bioactive substance carrier includes a bioactive substance and porous silica particles supporting the bioactive substance and having a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US20210228607A1

公开(公告)日：2021-07-29

申请号：US17051117

申请日：2019-04-24

Applicant: LEMONEX INC. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Cheol Hee WON ,  Dal Hee MIN

IPC: A61K31/7036 ,  A61K38/14 ,  A61K31/4706 ,  A61K31/5415 ,  A61K31/536 ,  A61K31/661 ,  A61K31/47 ,  A61K31/496 ,  A61K31/282 ,  A61K31/546 ,  A61K31/7048 ,  A61K38/12 ,  A61P31/14

Abstract: A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

公开(公告)号：US20210177988A1

公开(公告)日：2021-06-17

申请号：US17265692

申请日：2019-06-03

Applicant: LEMONEX INC.

Inventor： Cheol Hee WON

IPC: A61K47/69 ,  C07K16/28 ,  C07K14/55 ,  C07K14/54

Abstract: An immunoreactive substance carrier according to an embodiment of the present invention may stably deliver various immunoreactive substances including antibodies and/or cytokines, to a target site, thereby exhibiting excellent immunotherapeutic effects. Therefore, a composition including the immunoreactive substance carrier can be used for immunotherapy, thereby having excellent effects in the prevention or treatment of cancer or various immune diseases.

公开(公告)号：US20200163885A1

公开(公告)日：2020-05-28

申请号：US16633849

申请日：2018-07-25

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61L24/02 ,  A61L24/00 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/44 ,  A61K31/203 ,  A61K38/17 ,  C12N15/113 ,  A61K38/38 ,  C07K16/28 ,  A61K38/46 ,  A61K49/04

Abstract: A composition including porous silica particles according to an embodiment of the present invention may effectively deliver a bioactive material to target tissues or cells in the blood stream by modifying surfaces of the particles to inhibit aggregation and precipitation in the blood. An embolic composition including the composition may have an advantage of having specific physical properties such as biodegradability and sustained release thus to achieve excellent embolization effects and targetability toward target tumor tissues or cells, thereby reducing side effects.

公开(公告)号：US12234458B2

公开(公告)日：2025-02-25

申请号：US17162045

申请日：2021-01-29

Applicant: LEMONEX INC.

Inventor： Cheol Hee Won

IPC: C12N15/113 ,  A61K9/16 ,  A61P17/02 ,  C07K14/00

Abstract: A composition according to an embodiment of the present invention includes nucleic acid molecules which are capable of effectively inhibiting the expression level of connective tissue growth factor (CTGF) and collagen by RNA interference (RNAi), thereby preventing or treating a variety of fibroproliferative diseases due to overexpression of CTGF or collagen.

公开(公告)号：US20240261390A1

公开(公告)日：2024-08-08

申请号：US18563019

申请日：2022-05-30

Applicant: LEMONEX INC.

Inventor： CHEOL HEE WON

IPC: A61K39/215 ,  A61K9/14 ,  A61P31/14 ,  C07K14/005 ,  C07K19/00

CPC classification number: A61K39/215 ,  A61K9/143 ,  A61P31/14 ,  C07K14/005 ,  C07K19/00 ,  C12N2770/20034

Abstract: A nucleic acid molecule of RBD-(L)n-X sequence, wherein, RBD is a sequence of at least a partial region including the receptor-binding domain of the spike protein, L is a linker sequence, n is 0 or 1, and X is the nucleotide sequence of SEQ ID NO: 1 may be used in a vaccine composition against various viral infections.

公开(公告)号：US20240041771A1

公开(公告)日：2024-02-08

申请号：US18368097

申请日：2023-09-14

Applicant: LEMONEX INC.

Inventor： Cheolhee WON

IPC: A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

CPC classification number: A61K9/1611 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/1758 ,  A61K38/465 ,  A61K39/395

Abstract: A bioactive substance delivery system includes a bioactive substance comprising nucleic acid, and a bioactive substance carrier comprising a porous silica particle having a plurality of pores with a diameter of 5 nm to 100 nm, and having not less than 24 hours at which a ratio of absorbance is ½. The porous silica particles may be positively charged inside the pore at neutral pH.

公开(公告)号：US11779582B2

公开(公告)日：2023-10-10

申请号：US16476220

申请日：2018-01-08

Applicant: LEMONEX INC.

Inventor： Jae Ho Lee ,  Cheolhee Won

IPC: A61K31/506 ,  A23L33/10 ,  A61P35/04 ,  A61K33/243 ,  A61K31/165 ,  A61K31/337 ,  A61K31/343 ,  A61K31/475

CPC classification number: A61K31/506 ,  A23L33/10 ,  A61K31/165 ,  A61K31/337 ,  A61K31/343 ,  A61K31/475 ,  A61K33/243 ,  A61P35/04 ,  A23V2002/00

Abstract: A method for treatment of cancer selected from the group consisting of metastatic ovarian cancer, endometrial cancer, and breast cancer includes administering a composition comprising a compound represented by Formula 1, a pharmaceutically acceptable salt thereof to a subject in need thereof: The composition can efficiently kill cancer cells present in a spheroid form, thereby being usefully applied as novel medicament for metastatic ovarian cancer, endometrial cancer or breast cancer.

公开(公告)号：US11633447B2

公开(公告)日：2023-04-25

申请号：US17258312

申请日：2019-07-09

Applicant: LEMONEX INC.

Inventor： Cheol Hee Won ,  Jun Kim

IPC: A61K36/61 ,  A23L33/105 ,  A61P27/02 ,  A61K9/00

Abstract: A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration.

公开(公告)号：US11530132B2

公开(公告)日：2022-12-20

申请号：US16122872

申请日：2018-09-05

Applicant: LEMONEX INC.

Inventor： Dal-Hee Min ,  Cheolhee Won ,  Sejin Park ,  Seongchan Kim

IPC: C01B37/02 ,  C12N5/00 ,  A61K9/50 ,  B01J13/02 ,  B82Y5/00 ,  A61K9/51 ,  C12N5/077 ,  A61K31/711 ,  A61K45/06 ,  A61K31/352 ,  A61K47/69 ,  A61K31/196 ,  C12N5/079 ,  A61K31/706 ,  A61K31/437 ,  C12N5/071 ,  A61K35/12

Abstract: A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.